Please ensure Javascript is enabled for purposes of website accessibility

OncoImmune raises $56M in Series B financing for novel cancer and COVID-19 therapeutics (access required)

OncoImmune Inc., a privately-held, clinical-stage biopharmaceutical company in Rockville, Wednesday announced the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor. Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new investors, GBA Fund and GF Xinde, also joined the round. Oncoimmune will use ...

To purchase a reprint of this article, contact [email protected].